🧠 This Week in Immunology: Gene Therapy, Pediatric Breakthroughs & Rising Disease Trends
Stay up to date with the latest immunology news, featuring high-impact approvals, trial milestones, and policy shifts:
In this episode:
💥 Tremfya (Guselkumab) approved in the UK for Crohn’s Disease and Ulcerative Colitis—showing remission in over 50 percent of patients.
📈 Psoriasis and cellulitis cases sharply rise in the U.S., with cellulitis mortality increasing by nearly 40 percent.
📋 New expert guidelines aim to transform care for genital psoriasis, emphasizing psychosocial impact and personalized treatment.
🔐 Biofrontera secures Ameluz patent until 2043 and completes acne trial enrollment for its PDT-based therapy.
🧒 QRX003 delivers positive pediatric outcomes in Peeling Skin Syndrome—no adverse events reported.
🏥 First U.S. treatment center opens for ZEVASKYN, the first FDA-approved gene therapy for RDEB wounds.
🔬 CPT code expansion for excimer lasers broadens access to vitiligo, atopic dermatitis, and alopecia areata care.
💊 AAFA pushes for systemic drug pricing reform—calling for PBM rebate overhaul and better coverage protections.
🤝 AbbVie and ADARx announce $335M partnership to advance next-gen siRNA therapeutics in immunology and beyond.
📢 Stay Ahead in Immunology Research!
✅ Like, share, and subscribe for weekly updates on the latest in immunology and autoimmune diseases.
#Immunology #GeneTherapy #CrohnsDisease #PsoriasisTreatment #AutoimmuneResearch #HealthcareInnovation #ClinicalTrials #DermatologyNews #LucidQuest #ImmunologyUpdates